| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 04/02/2013 | US8409590 Anthrax antigens and methods of use |
| 04/02/2013 | US8409589 Mutant forms of streptolysin O |
| 04/02/2013 | US8409588 Recombinant foot and mouth disease vaccine |
| 04/02/2013 | US8409587 Immunogenic composition |
| 04/02/2013 | US8409584 Immunotherapy targeting of the shared abnormal conformational state of amyloidogenic peptides/proteins |
| 04/02/2013 | US8409583 Engineered versions of CgtB (β-1,3 galactosyltransferase) enzymes, with enhanced enzymatic properties |
| 04/02/2013 | US8409582 Purified linear epitopes from cashew nuts, nucleic acids encoding therefor, and associated methods |
| 04/02/2013 | US8409581 Compounds for treating amyloidoses |
| 04/02/2013 | US8409580 Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers |
| 04/02/2013 | US8409579 Humanized anti-FGF19 antagonists and methods using same |
| 04/02/2013 | US8409578 Methods for treating bone loss with antibodies to OPGL |
| 04/02/2013 | US8409577 Single chain multivalent binding proteins with effector function |
| 04/02/2013 | US8409576 Use of IL-1beta compounds |
| 04/02/2013 | US8409575 Antibodies specific for amyloid beta protofibril |
| 04/02/2013 | US8409574 Taxane analogs for the treatment of brain cancer |
| 04/02/2013 | US8409573 Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells |
| 04/02/2013 | US8409572 Monoclonal antibodies with enhanced ADCC function |
| 04/02/2013 | US8409571 Methods of antagonizing signal transduction in spinal cord cells |
| 04/02/2013 | US8409570 Method of inducing apoptosis using anti-DR5 antibodies |
| 04/02/2013 | US8409569 Compositions and methods for diagnosing and treating an inflammation |
| 04/02/2013 | US8409568 Mutant antibody Fc domains and fusion proteins thereof |
| 04/02/2013 | US8409567 Toll-like receptor 3 antagonists |
| 04/02/2013 | US8409566 Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis |
| 04/02/2013 | US8409565 Therapeutic target and diagnostic marker for asthma and related conditions |
| 04/02/2013 | CA2772962C Method of preparing plant-derived vlps |
| 04/02/2013 | CA2565424C Macromolecule-containing sustained release intraocular implants and related methods |
| 04/02/2013 | CA2553883C Anti-cancer antibodies with reduced complement fixation |
| 04/02/2013 | CA2532799C Human antibody molecules for il-13 |
| 04/02/2013 | CA2531441C Hybrid toxins comprising shiga or shiga-like toxin subunits fused to escherichia coli heat labile enterotoxin subunits and vaccines thereof |
| 04/02/2013 | CA2529363C Quil a fraction with low toxicity and use thereof |
| 04/02/2013 | CA2513813C Novel method for isolating endotoxins |
| 04/02/2013 | CA2512108C Certain aminoalkyl glucosaminide phosphate compounds and their use |
| 04/02/2013 | CA2471145C Dna encoding novel cyclic gmp dependent protein kinases from two protozoal sources for use as chemotherapeutic targets for antiprotozoal agents |
| 04/02/2013 | CA2460392C Recombinant allergen with reduced ige binding but undiminished t-cell antigenicity |
| 04/02/2013 | CA2453062C Group b streptococcus bvh-a5 antigens and corresponding dna fragments |
| 04/02/2013 | CA2420543C Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers |
| 04/02/2013 | CA2396212C Recombinant antibodies to human interleukin-1 beta |
| 04/02/2013 | CA2201282C Viral material and nucleotide fragments associated with multiple sclerosis useful for diagnostic, preventive and therapeutic purposes |
| 03/28/2013 | WO2013044215A1 Vegf/dll4 binding agents and uses thereof |
| 03/28/2013 | WO2013044203A2 Novel influenza hemagglutinin protein-based vaccines |
| 03/28/2013 | WO2013044177A2 Bacterial strains expressing methylase genes and uses thereof |
| 03/28/2013 | WO2013044147A1 Vaccine therapy |
| 03/28/2013 | WO2013044061A1 Plant viral vaccines and therapeutics |
| 03/28/2013 | WO2013043973A2 Cachexia treatment |
| 03/28/2013 | WO2013043933A2 Cd27l antigen binding proteins |
| 03/28/2013 | WO2013043800A1 Anti-hla-dr antibodies suppress allogeneic and xenogeneic immune responses to organ transplants |
| 03/28/2013 | WO2013043729A1 Influenza virus vaccines and uses thereof |
| 03/28/2013 | WO2013043715A1 Combination treatments comprising c-met antagonists and b-raf antagonists |
| 03/28/2013 | WO2013043647A1 Cancer immunotherapy |
| 03/28/2013 | WO2013043644A1 Methods using liver disease biomarkers |
| 03/28/2013 | WO2013043643A1 Live, attenuated streptococcus pneumoniae strain and vaccine for protection against pneumococcal disease |
| 03/28/2013 | WO2013043569A1 Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
| 03/28/2013 | WO2013043452A1 Anti-c-met antibodies |
| 03/28/2013 | WO2013043128A1 Sall4 and uses thereof |
| 03/28/2013 | WO2013043125A1 Enterovirus 71 specific antibodies and uses thereof |
| 03/28/2013 | WO2013043071A1 Modified albumin-binding domains and uses thereof to improve pharmacokinetics |
| 03/28/2013 | WO2013043067A2 Dna vaccine, method of inducing the immune response, method of immunisation, antibodies specifically recognising the h5 haemagglutinin of an influenza virus and use of the dna vaccine |
| 03/28/2013 | WO2013042053A2 Compounds for use in the treatment of alzheimer's disease |
| 03/28/2013 | WO2013041966A1 Vaccibodies targeted to cross-presenting dendritic cells |
| 03/28/2013 | WO2013041962A1 Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease |
| 03/28/2013 | WO2013041722A1 Prolonged inhibition of interleukin-6 mediated signaling |
| 03/28/2013 | WO2013041677A1 Combination therapy using immunoglobulin and c1-inhibitor |
| 03/28/2013 | WO2013041673A1 Modified gram positive bacteria and uses thereof |
| 03/28/2013 | WO2013041238A1 Use of kibra peptides, hdac inhibitor or proteasome inhibitor for improving anxiety disorders |
| 03/28/2013 | WO2013041029A1 Novel soluble ctla4 variants |
| 03/28/2013 | WO2013040766A1 Method and vaccine capable of inducing broad spectrum immune response against hiv |
| 03/28/2013 | WO2013040648A1 Pneumococcal glpo immunogen |
| 03/28/2013 | WO2013019889A3 Bovine polyclonal antibody specific for human tnf |
| 03/28/2013 | WO2012178196A3 Protection against dengue virus and prevention of severe dengue disease |
| 03/28/2013 | WO2012177595A9 Compositions and methods for the therapy and diagnosis of cancer |
| 03/28/2013 | WO2012165925A3 Anti-c-met antibody having hgf activity and use thereof |
| 03/28/2013 | WO2012159120A3 Gene therapy based strategy for treating hiv |
| 03/28/2013 | WO2012149334A3 Methods and compositions for the generation and use of conformation-specific antibodies |
| 03/28/2013 | WO2012076157A3 Malaria vaccines based on pre-erythrocytic antigens from p. falciparum |
| 03/28/2013 | WO2008076278A8 Methods of cancer treatment with igf1r inhibitors |
| 03/28/2013 | US20130079390 Nucleic acid molecules, polypeptides, antibodies and compositions for treating and detecting influenza virus infection |
| 03/28/2013 | US20130078281 Activators of innate immunity |
| 03/28/2013 | US20130078278 Vaccine for protection against shigella sonnei disease |
| 03/28/2013 | US20130078277 Infectious hepatitis c virus-high producing hcv variants and use thereof |
| 03/28/2013 | US20130078274 Live, oral vaccine for protection against shigella dysenteriae serotype 1 |
| 03/28/2013 | US20130078273 Vault Compositions For Immunization |
| 03/28/2013 | US20130078271 Nucleic acid and amino acid sequences relating to streptococcus pneumoniae for diagnostics and therapeutics |
| 03/28/2013 | US20130078269 Amyloid beta peptides, assemblies thereof, and related methods |
| 03/28/2013 | US20130078268 Vaccine compositions and methods of use thereof |
| 03/28/2013 | US20130078267 Epitopes Related To Coeliac Disease |
| 03/28/2013 | US20130078266 Immunosuppression By Blocking T Cell Co-Stimulation Signal 2 (B7/CD28 Interaction) |
| 03/28/2013 | US20130078265 Laser-based vaccine adjuvants |
| 03/28/2013 | US20130078264 Removal of serine proteases by treatment with finely divided silicon dioxide |
| 03/28/2013 | US20130078263 Anti-HLA-DR Antibodies Suppress Allogeneic and Xenogeneic Immune Responses to Organ Transplants |
| 03/28/2013 | US20130078261 Enveloped virus vaccine and method for production |
| 03/28/2013 | US20130078260 Compounds targeting the vegf and/or hif pathway such as sorafenib or vatalanib for use in the treatment of otitis media |
| 03/28/2013 | US20130078259 Method of diagnosing and preventing pneumococcal diseases using pneumococcal neuraminidases |
| 03/28/2013 | US20130078258 Cachexia Treatment |
| 03/28/2013 | US20130078257 Use of an active substance binding to cd28 for producing a pharmaceutical composition for the treatment of b-cll |
| 03/28/2013 | US20130078256 Novel hiv reverse transcriptase inhibitors |
| 03/28/2013 | US20130078254 Genes of an otitis media isolate of nontypeable haemophilus influenzae |
| 03/28/2013 | US20130078253 Cancer targets and uses thereof |
| 03/28/2013 | US20130078252 Combination treatments comprising c-met antagonists and b-raf antagonists |
| 03/28/2013 | US20130078243 Conjugate molecule |
| 03/28/2013 | US20130078242 Antibodies With Immune Effector Activity And That Internalize In Endosialin-Positive Cells |